In the last few decades, the role of minimally invasive (laparoscopic and robotic) surgery in the management of patients with gynecological malignancies has increasingly been investigated. It has largely been demonstrated that a minimally invasive approach offers significant benefits in terms of lower rate of surgical site infection, transfusion, venous thromboembolism, decreased hospital stay, and lower cost of care when compared with laparotomy. Therefore, a minimally invasive surgery is the preferred approach when technically feasible and able to provide survival outcomes superimposable to those reported after traditional open surgery (◘ Fig. 96.1).